The guidelines, published today, are due to be presented to the European Parliament, the European Patent Office and the European Commission in a bid to stimulate their incorporation into patent law.
Professor Gert Matthijs of the Catholic University of Leuven, who chaired the investigation, believes a major breakthrough has been made. “ESHG has a well respected history of researching and issuing recommendations on different aspects of genetic testing. As soon as the first monopolies on genetic tests started appearing, we realised patenting had become a major issue.”
“This new proposal aims to reconcile what until now have appeared to be conflicting interests of patent owners, commercial companies, health authorities, policy makers, and geneticists, with the ultimate goal of ensuring that patients retain access to the latest technological advances,” said Matthijs.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
